CD8+ T cell immunity to Epstein-Barr virus and Kaposi's sarcoma-associated herpes virus.

Andrew Hislop, S Sabbah

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Gammaherpesviruses are agents which have evolved to persist within the lymphoid system and many have oncogenic potential; studying gammaherpesvirus infections therefore has the potential to reveal much about the workings of the immune system and the control over viral oncogenesis. The lymphocryptovirus Epstein-Barr virus (EBV) and the rhadinovirus Kaposi's sarcoma-associated herpesvirus (KSHV, also known as human herpesvirus 8) are the two human gammaherpesviruses. Analysis of the T cell response to EBV has guided understanding of immunity to infection and disease caused by this virus, as well as directed the development of vaccination and therapeutic interventions in EBV-associated disease. Less is known about the T cell response to KSHV and its exact role in controlling virus infection and disease. Here we discuss the CD8+ T cell response to these two gammaherpesviruses.
Original languageEnglish
Pages (from-to)416-22
Number of pages7
JournalSeminars in Cancer Biology
Volume18
Issue number6
DOIs
Publication statusPublished - 1 Dec 2008

Keywords

  • Epstein-Barr virus
  • Cellular immunology
  • Kaposi's sarcoma-associated herpesvirus
  • CD8 T cell

Fingerprint

Dive into the research topics of 'CD8+ T cell immunity to Epstein-Barr virus and Kaposi's sarcoma-associated herpes virus.'. Together they form a unique fingerprint.

Cite this